VIPDOMET 12.5/1000; 12.5 mg alogliptin (as benzoate) / 1000 mg metformin hydrochloride film-coated tablets blister pack

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

metformin hydrochloride, Quantity: 1000 mg; alogliptin benzoate, Quantity: 17 mg (Equivalent: alogliptin, Qty 12.5 mg)

Verfügbar ab:

Takeda Pharmaceuticals Australia Pty Ltd

INN (Internationale Bezeichnung):

Alogliptin benzoate,Metformin hydrochloride

Darreichungsform:

Tablet, film coated

Zusammensetzung:

Excipient Ingredients: mannitol; purified talc; iron oxide yellow; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; crospovidone; hypromellose

Verabreichungsweg:

Oral

Einheiten im Paket:

120, 112, 180, 56, 60, 14, 10, 196, 28, 98, 200, 20

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

VIPDOMET is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,VIPDOMET can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Produktbesonderheiten:

Visual Identification: Pale yellow, oblong, biconvex, film-coated tablets with 12.5/1000 debossed on one side and 322M debossed on the other side.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2013-10-22